1. Home
  2. UTHR vs WLK Comparison

UTHR vs WLK Comparison

Compare UTHR & WLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • UTHR
  • WLK
  • Stock Information
  • Founded
  • UTHR 1996
  • WLK 1986
  • Country
  • UTHR United States
  • WLK United States
  • Employees
  • UTHR N/A
  • WLK N/A
  • Industry
  • UTHR Biotechnology: Pharmaceutical Preparations
  • WLK Major Chemicals
  • Sector
  • UTHR Health Care
  • WLK Industrials
  • Exchange
  • UTHR Nasdaq
  • WLK Nasdaq
  • Market Cap
  • UTHR 14.4B
  • WLK 13.8B
  • IPO Year
  • UTHR 1999
  • WLK 2004
  • Fundamental
  • Price
  • UTHR $306.97
  • WLK $99.14
  • Analyst Decision
  • UTHR Buy
  • WLK Buy
  • Analyst Count
  • UTHR 12
  • WLK 14
  • Target Price
  • UTHR $388.25
  • WLK $136.07
  • AVG Volume (30 Days)
  • UTHR 492.5K
  • WLK 891.4K
  • Earning Date
  • UTHR 04-30-2025
  • WLK 04-30-2025
  • Dividend Yield
  • UTHR N/A
  • WLK 2.12%
  • EPS Growth
  • UTHR 24.38
  • WLK 25.41
  • EPS
  • UTHR 24.64
  • WLK 4.64
  • Revenue
  • UTHR $2,877,400,000.00
  • WLK $12,142,000,000.00
  • Revenue This Year
  • UTHR $11.70
  • WLK $3.32
  • Revenue Next Year
  • UTHR $6.50
  • WLK $6.41
  • P/E Ratio
  • UTHR $12.40
  • WLK $21.36
  • Revenue Growth
  • UTHR 23.63
  • WLK N/A
  • 52 Week Low
  • UTHR $221.53
  • WLK $98.51
  • 52 Week High
  • UTHR $417.82
  • WLK $162.64
  • Technical
  • Relative Strength Index (RSI)
  • UTHR 39.02
  • WLK 34.03
  • Support Level
  • UTHR $308.43
  • WLK $100.07
  • Resistance Level
  • UTHR $318.40
  • WLK $103.19
  • Average True Range (ATR)
  • UTHR 9.26
  • WLK 3.24
  • MACD
  • UTHR 1.20
  • WLK -0.38
  • Stochastic Oscillator
  • UTHR 29.88
  • WLK 4.87

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

About WLK Westlake Corporation

Westlake Corp is a manufacturer and supplier of chemicals, polymers, and building products. Its Performance and Essential Materials segment offers a wide range of essential building blocks for making products utilized in everyday living, including olefins, vinyl chemicals, polyethylene, and epoxies. Its Housing and Infrastructure Products segment produces key finished goods for building products, pipe and fittings, and global compounds businesses.

Share on Social Networks: